Medigen Vaccine Biologics (6547 TWO) stock market data APIs
NT$49.7
0.65(1.3%)
as of January 22, 2025
Medigen Vaccine Biologics Financial Data Overview
Price chart is built with
Anychart
Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Zhubei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.
Prev. Close
49.05
Open
49.7
Volume
1 282 K
High
50
Low
49.05
52 wk Range
33.7-66
Market Cap
12 359 M
Shares Outstanding
329 M
Revenue
623 M
EPS
-1.77
Beta
0.75
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Medigen Vaccine Biologics data using free add-ons & libraries
Get Medigen Vaccine Biologics Fundamental Data
Medigen Vaccine Biologics Fundamental data includes:
- Net Revenue: 623 M
- EBITDA: -624 742 016
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-03-08
- EPS/Forecast: -0.49
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Medigen Vaccine Biologics News
New
Dynavax (DVAX) Gains as Medigen Rolls Out COVID-19 Vaccine
Shares of Dynavax Technologies Corporation DVAX jumped 14.4% after its Taiwan-based partner Medigen Vaccine Biologics Corporation announced the rollout of its COVID-19 vaccine — MVC-COV1901 — in t...
Powered By Dynavax Adjuvant, Medigen COVID-19 Vaccine Launched In Taiwan
Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation (NASDAQ: DVAX) announced the rollout of their COVID-19 vaccine, MVC-COV1901, in Taiwan. Approximately 600,000 people are anti...
Taiwan's Medigen to start late-stage clinical trial for COVID-19 vaccine in Paraguay
TAIPEI, July 20 (Reuters) - Taiwan's Medigen Vaccine Biologics Corp said on Tuesday it will start a late-stage clinical trial this year in Paraguay for its COVID-19 vaccine, part of the island's push ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
